这项发现为我们提供了一个全新的视角来评估免疫治疗的长期效果。通过检测患者肿瘤组织中前体耗竭性T细胞（Texp）的比例，我们或许能够更准确地预测他们未来复发的风险，从而为制定更个体化的治疗和随访策略提供依据。

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

天津医科大学肿瘤医院郝继辉教授团队等在 Cell Research 期刊发表了题为： Nociceptor neurons promote PDAC progression and cancer pain by interaction with ...

French cell therapy company Celyad is also working ... aim to stimulate the body's natural killer cells to fight cancer - but the future of this therapy is uncertain after disappointing trial ...

If preclinical findings were translated into clinic, they could shorten CAR-T generation lead time to one day.

Wistar scientists have labeled this new approach "NuKES": Natural Killer Enhancement Strategy ... "This exciting improvement ...

Certain subsets of immune NK cells were altered in the blood of people with ALS, and could serve as therapeutic targets, a ...

First NK Cell Therapy Approval Expected By 2028 Says Kuick Research In Its New Research Study On Global NK Cell Therapy ...

Among other functions, the NK cells (natural killers, a type of lymphocyte forming part of the immune system) have the capacity to detect and eliminate cancer cells. But in some cases they cannot ...

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science ...

The aggregate gross proceeds to the Company from the offering were approximately $5.0 million before deducting the placement agent's fees and other offering expenses payable by the Company. The ...